ANA means antinuclear antibody. A positive result signals that immune proteins bind nuclear material, but it does not by itself diagnose lupus or another autoimmune disease.
- ANA meaning: ANA stands for antinuclear antibody, an immune protein that reacts with material inside cell nuclei.
- Positive ANA result: Up to 13.8% of people in the United States have an ANA at a 1:80 screening dilution, many without autoimmune disease.
- Test method: HEp-2 indirect immunofluorescence reports both a titre, such as 1:160, and a fluorescence pattern.
- Co-theacsa clionaigeach: A positive ANA carries more weight with inflammatory joint swelling, photosensitive rash, mouth ulcers, low complement, or kidney findings.
- Titre threshold: A 1:80 ANA is the entry criterion for 2019 EULAR/ACR lupus classification, not a diagnosis of lupus.
- Deuchainnean an ath rud: Anti-dsDNA, ENA antibodies, C3, C4, urinalysis, CBC, and kidney function are selected by symptoms rather than ordered automatically.
- Fìor dhealbhaidhean (false positives): Age, recent viral illness, thyroid autoimmunity, some medicines, and healthy immune variation can produce ANA positivity.
- comharran èiginneach: Foamy urine, leg swelling, chest pain with breathing, confusion, new seizures, or rapidly worsening breathlessness need prompt medical assessment.
ANA Meaning: What the Letters Actually Stand For
ANA stands for antinuclear antibody. The antinuclear antibody test looks for antibodies that bind components within a cell nucleus; it is a screening clue, not a standalone autoimmune diagnosis. As of September 14, 2026, that distinction remains the part patients most often miss when a portal simply displays “positive.”
Antibodies normally help identify infections, yet some also recognize the body’s own proteins. ANA testing detects this reactivity in a laboratory cell substrate, usually HEp-2 cells, and reports whether fluorescent binding is present at serial dilutions such as 1:80 or 1:160. A positive result says the antibody exists; it does not say it is causing symptoms.
In my clinical practice, I have met patients frightened by a 1:320 result who had no autoimmune illness after careful review, and others with a lower titre plus kidney protein and classic symptoms who needed urgent rheumatology care. Dr. Thomas Klein’s practical rule is simple: the pre-test probability matters as much as the titre.
Tha Kantesti na Anailisiche deuchainn fala AI that places ANA-related findings beside CBC, kidney, liver, and inflammatory markers rather than treating one antibody flag as a verdict. Our stiùireadh fiosrachaidh bith-chomharran explains why a laboratory flag is only the start of interpretation.
Why “antinuclear” can sound more alarming than it is
The word “nuclear” refers to the nucleus of a laboratory cell, not radiation or cancer. Nuclear staining is a technical observation, and different staining patterns may point toward different follow-up antibodies.
Why Clinicians Order an Antinuclear Antibody Test
Clinicians order an ANA when the history or examination suggests a systemic autoimmune connective-tissue disease. The test is most useful for persistent inflammatory features, not as a broad check-up for tiredness alone.
Features that raise the value of an ANA include swollen joints lasting more than 6 weeks, Raynaud-type colour changes, sun-sensitive rash, recurrent mouth ulcers, unexplained low white cells, pleuritic chest pain, or protein in urine. A normal examination and nonspecific fatigue make a positive result much harder to interpret.
The 2019 EULAR/ACR lupus classification criteria use ANA positivity at a titre of at least 1:80 as an entry criterion, then require weighted clinical and immunologic features; classification is not the same as making an individual diagnosis (Aringer et al., 2019). This design prevents a screening test from doing work it cannot do.
A useful parallel is the rheumatoid factor titre—antibodies must be read with symptoms, examination, and objective findings. Ordering an ANA after a viral illness or during a low-probability work-up often creates uncertainty rather than clarity.
Symptoms that deserve a targeted review
A clinician will usually ask whether stiffness lasts over 30 to 60 minutes after waking, whether fingers change colour in cold conditions, and whether urine has become persistently foamy. Those details can change the next test far more than repeating ANA alone.
How the ANA Test Is Measured and Reported
Most laboratories measure ANA with indirect immunofluorescence on HEp-2 cells and report a titre plus a staining pattern. The titre is the greatest dilution at which fluorescence remains visible, so 1:640 reflects more detectable binding than 1:80.
A titre is not a concentration in mg/dL or IU/L. At a 1:80 dilution, one unit of serum is diluted into 79 units of diluent; at 1:320, the sample has undergone two additional two-fold dilutions. Labs vary in their positivity thresholds, which is why the original report matters.
Patterns may be described as homogeneous, speckled, centromere, nucleolar, or cytoplasmic. A centromere pattern can support testing for limited cutaneous systemic sclerosis in the right setting, while a dense fine speckled pattern may occur in people without systemic autoimmune rheumatic disease; pattern alone still does not diagnose anyone.
Some laboratories use solid-phase screening assays first, while others use immunofluorescence as the primary test. If results conflict, ask which method and cut-off were used before assuming your immune system changed; our stiùireadh deuchainn càileachdail an aghaidh tomhasail explains why methods can answer different questions.
Why a Positive ANA Result Does Not Diagnose Lupus
A positive ANA result does not diagnose lupus because ANA is sensitive but not specific for lupus. Many healthy people and people with unrelated conditions have detectable ANA, whereas lupus diagnosis requires a coherent clinical pattern.
In the U.S. National Health and Nutrition Examination Survey sample, ANA prevalence was 13.8% overall using HEp-2 immunofluorescence at 1:80, and prevalence rose with age (Satoh et al., 2012). That number explains why screening people with vague symptoms can produce many false alarms.
Lupus becomes more plausible when ANA coexists with anti-dsDNA or anti-Sm antibodies, low C3 or C4, active urine sediment, proteinuria, inflammatory arthritis, or characteristic skin disease. A normal urinalysis and normal complement do not erase symptoms, but they reduce concern for active immune-complex kidney involvement.
An stiùiridh toradh anti-dsDNA is useful when that specific antibody appears on your report. Do not compare your titre with another patient’s online; laboratory substrate, pattern, symptoms, and time course differ.
Sensitivity versus specificity in plain language
ANA is sensitive for systemic lupus erythematosus, meaning most affected people have it, but it lacks specificity because it also occurs outside lupus. A test with that profile is best used to support or question a clinical suspicion, not to create one.
Common Reasons ANA Can Be Positive Without Lupus
ANA can be positive in healthy people, after some infections, with autoimmune thyroid disease, chronic liver conditions, and certain medicines. A positive result becomes clinically meaningful only when its cause fits the person’s symptoms and other tests.
Age and sex influence background positivity: ANA occurs more often in women and becomes more common in older adults. A transient response can follow viral immune activation, so repeating a low-positive ANA immediately after an acute febrile illness is usually less informative than waiting for the clinical picture to settle.
Drug-induced lupus is uncommon but classically associated with medicines such as hydralazine, procainamide, isoniazid, minocycline, and anti-TNF therapies. The relevant pattern is symptoms beginning after exposure, often with antihistone antibodies; never stop a prescribed medicine based solely on an ANA flag.
Autoimmune thyroid disease can coexist with ANA positivity, but thyroid symptoms need thyroid-specific interpretation rather than a rheumatology diagnosis. If thyroid antibodies are present, see our review of antibodies TPO àrd for sensible follow-up questions.
A negative infectious screen is not the whole story
Recent Epstein-Barr virus infection and other immune triggers can alter antibody testing, but timing and antibody pattern are needed to interpret it. A detailed EBV antibody pattern is more useful than guessing from fatigue alone.
How Much Does an ANA Titre Matter?
Higher ANA titres generally increase the likelihood of a clinically relevant autoimmune disease, but no titre alone confirms one. A 1:640 result deserves more context than 1:80, not a faster diagnosis.
Titre interpretation depends on the patient in front of you. In a person with no inflammatory symptoms, a 1:160 speckled ANA may lead only to education and observation; in someone with new proteinuria and low C3, even a modest titre can be part of an urgent assessment.
There is no universal “dangerous ANA number.” Some European laboratories use 1:160 rather than 1:80 as their screening threshold to improve specificity, while the 2019 EULAR/ACR lupus framework intentionally accepts 1:80 as a sensitive entry point (Aringer et al., 2019).
Kantesti’s seirbheis eadar-mhìneachaidh deuchainn-lann AI identifies the reported method, titre, and accompanying abnormalities when they are available, then encourages clinician review for concerning combinations. Tracking a single antibody upwards or downwards is usually less useful than following C3 and C4 complement results and organ-specific findings.
Why titre changes can disappoint patients
ANA titres can fluctuate because of laboratory technique and biological variation. In established lupus, anti-dsDNA, complements, urine protein, symptoms, and examination usually tell us more about current activity than repeating ANA every few months.
ANA Patterns: Helpful Clues, Not Diagnostic Labels
ANA patterns can guide selective follow-up testing, but they cannot name a disease by themselves. The same speckled pattern, for example, may occur with anti-Ro, anti-RNP, anti-Sm, or no clinically significant antibody.
A homogeneous pattern is often associated with antibodies to chromatin, histones, or double-stranded DNA, while a centromere pattern can point toward anticentromere antibody testing. Nucleolar staining may prompt consideration of systemic sclerosis spectrum disease when skin, lung, or Raynaud features are present.
Dense fine speckled staining associated with DFS70 antibodies is a frequent source of anxiety. Isolated anti-DFS70 antibodies, particularly with no ENA antibodies and no suggestive symptoms, may make a systemic autoimmune rheumatic disease less likely, although laboratories do not all report or confirm this the same way.
The most practical question is not “Which disease matches this pattern?” but “Which confirmatory test would change management?” A toradh antibody deimhinneach should lead to targeted questions, not a scattershot panel.
Cytoplasmic patterns are different
Some reports list cytoplasmic staining separately because the target is outside the nucleus. That can matter in autoimmune liver or muscle work-ups, but it should not be casually described as a positive nuclear ANA.
Tests That May Follow a Positive ANA
Follow-up after a positive ANA should be symptom-led and may include anti-dsDNA, extractable nuclear antigen antibodies, C3, C4, CBC, creatinine, and urinalysis. Testing every autoimmune antibody at once increases incidental findings and often does not improve care.
When lupus is suspected, clinicians commonly check anti-dsDNA, anti-Sm, C3, C4, serum creatinine, urine protein, and urine sediment. Proteinuria of at least 0.5 g per day, or an equivalent urine protein-to-creatinine ratio, is one finding that deserves timely medical evaluation in a compatible autoimmune picture.
Anti-Ro/SSA and anti-La/SSB testing may be appropriate with dry eyes, dry mouth, photosensitive rash, or pregnancy planning, while RNP may be selected for mixed connective-tissue disease features. For muscle weakness, creatine kinase and sometimes aldolase matter more than expanding ANA panels; see high aldolase follow-up.
Kantesti AI interprets an ANA-related panel by looking for cross-panel consistency, including low complement, cytopenias, kidney signals, and liver enzymes. It does not replace examination, microscopy, or a rheumatologist’s diagnosis.
Urine testing is often underappreciated
Urinalysis can identify protein, red cells, and cellular casts that change the urgency of a lupus work-up. Persistent pròtain san fhuaim should be evaluated whether ANA is positive or negative.
Should You Repeat an ANA Test?
Repeating ANA is usually unnecessary when a prior result is clearly positive and symptoms have not changed. ANA does not reliably track disease activity, so repeat testing often adds cost and confusion rather than useful information.
A repeat ANA may make sense if the original result was borderline, the laboratory method was unclear, or a major new clinical syndrome has appeared years later. For established lupus, clinicians more often monitor urine protein, creatinine, C3, C4, anti-dsDNA when relevant, and blood counts.
I tell patients that an ANA can remain positive for years, even when they feel entirely well. Treating a number that has no accompanying illness is a common source of unnecessary referrals, repeat panels, and avoidable worry.
Longitudinal context beats a single portal flag. Our stiùireadh atharrachaidh deuchainn fala explains biological variation and why a small laboratory shift is not always a medical shift.
Do symptoms change the plan?
Yes. New joint swelling, a new photosensitive eruption, recurrent fevers, unexplained low cell counts, or urinary changes should prompt clinical review even if the ANA was tested months earlier. The reason to reassess is the new syndrome, not the old positive test.
ANA Results in Pregnancy and Before Conception
ANA positivity alone does not predict pregnancy complications, but specific antibodies and a history of autoimmune disease can change obstetric planning. Anti-Ro/SSA and anti-La/SSB deserve particular attention because they can cross the placenta.
A person with a positive ANA who is planning pregnancy should not assume danger, but should discuss symptoms and any known anti-Ro/SSA, anti-La/SSB, antiphospholipid, or lupus history with their clinician. Maternal anti-Ro/SSA positivity can lead to fetal rhythm surveillance in selected circumstances, even when the mother feels well.
Pregnancy also changes baseline laboratory interpretation: albumin falls through haemodilution, eGFR rises early, and complement levels may be higher than non-pregnant baselines. A “normal” C3 during pregnancy can therefore be less reassuring if it has fallen sharply from that person’s earlier level.
Pregnancy testing is safest when organised around the reason for testing. Review pregnancy kidney filtration values alongside obstetric care rather than interpreting an isolated creatinine or ANA on its own.
Antiphospholipid antibodies are separate tests
ANA does not test for lupus anticoagulant, anticardiolipin, or anti-beta-2 glycoprotein I antibodies. These are distinct tests considered after thrombosis, certain pregnancy complications, or when a specialist identifies a relevant clinical pattern.
ANA Testing in Children and Teenagers
ANA is especially prone to over-interpretation in children because low-level positivity can occur without rheumatic disease. A child’s joint examination, fever pattern, rash, growth, and eye symptoms matter more than an isolated screening result.
In children with juvenile idiopathic arthritis, ANA may help identify those needing regular slit-lamp eye screening for asymptomatic uveitis, but it does not diagnose arthritis. A child without swollen joints or systemic features should not be labelled with lupus because of a positive screen.
Paediatric reference intervals are not simply scaled-down adult ranges, and the emotional fallout of an unexplained test can be substantial. I have seen families avoid school sports after a low-positive ANA despite a normal examination; clear reassurance and a written safety-net plan are often the best intervention.
Tha Kantesti na Inneal mion-sgrùdaidh deuchainn fala le cumhachd AI that can organise paediatric laboratory reports, but its output should be reviewed with a paediatric clinician because age, growth, and medication doses alter meaning. Our guide on mìneachadh AI airson clann outlines those limits.
Eye symptoms should not be ignored
A painful red eye, light sensitivity, or reduced vision needs prompt ophthalmic assessment regardless of ANA status. In juvenile arthritis, uveitis can be silent, which is why screening schedules are set by rheumatology and ophthalmology rather than by symptoms alone.
When a Positive ANA Needs Prompt Medical Review
A positive ANA needs prompt assessment when it accompanies kidney symptoms, chest pain with breathing, new neurologic symptoms, severe shortness of breath, rapidly progressive rash, or objectively swollen joints. The urgency comes from possible organ involvement, not from the antibody number alone.
Seek urgent care for new confusion, seizure, coughing blood, severe chest pain, fainting, rapidly worsening breathlessness, or markedly reduced urine output. These symptoms have many possible causes, but autoimmune disease is one reason clinicians may check kidney function, urine, complements, and imaging quickly.
Foamy urine, ankle swelling, or blood visible in urine should prompt timely testing for urine protein, sediment, creatinine, and blood pressure. A normal creatinine does not completely exclude early kidney involvement because filtration may remain preserved while urinary protein is already abnormal.
An low complement result guide explains why low C3 and C4 can matter when paired with symptoms. Do not wait for a repeat ANA if red-flag symptoms are developing.
What is usually not an emergency
An isolated positive ANA with no symptoms, normal urine, and normal examination is rarely an emergency. Arrange routine follow-up, bring the original report, and avoid urgent repeat testing unless a clinician identifies a new concern.
How to Prepare for an ANA Follow-Up Appointment
Bring the original ANA report, symptom timeline, medication list, and prior laboratory results to an ANA follow-up appointment. The report’s method, titre, and pattern often matter more than the word “positive” copied into a portal summary.
Write down when symptoms began, whether they are episodic, what triggers them, and whether photos document a rash before it fades. Include family history of lupus, thyroid disease, psoriasis, inflammatory arthritis, clotting, or kidney disease, but remember that family history raises context rather than establishes diagnosis.
Ask three practical questions: What condition are we considering? Which result would change treatment? What symptoms should make me call sooner? A clinician who can answer those clearly is less likely to order an indiscriminate antibody panel.
Kantesti AI can help arrange a laboratory PDF into questions for your appointment and compare prior values, while clinical interpretation remains with your care team. Our doctor-visit laboratory checklist can help you capture the essentials.
Avoid supplements marketed to “lower ANA”
No supplement has been proven to safely erase an ANA or prevent lupus in an otherwise well person. Starting high-dose products can complicate liver tests, kidney tests, and medication interactions without treating the underlying question.
How Kantesti Places ANA Results in Clinical Context
Kantesti does not diagnose lupus from an ANA result; it highlights whether related laboratory findings support a conversation with a clinician. This is safer because ANA interpretation depends on symptoms, examination, laboratory method, and organ-specific evidence.
Kantesti AI ’s e àrd-ùrlar mìneachaidh biomarcadairean AI that reviews ANA-associated results alongside creatinine, eGFR, urine findings, CBC, liver markers, and complement values when supplied. A low C3 plus urinary protein and falling platelets is a more meaningful follow-up signal than ANA positivity by itself.
Our clinical team reviews methodology and safety boundaries through the frèam-obrach dearbhaidh meidigeach. In my experience, a structured report is most useful when it helps a patient ask better questions—not when it pretends to replace a physical examination.
Kantesti supports users in 127+ countries and 75+ languages with privacy-focused handling, but it cannot inspect a rash, feel joint warmth, or decide whether a new symptom is urgent. For complex results, our Bòrd Comhairleachaidh Meidigeach reflects the clinician oversight that should remain central.
A better way to use an AI interpretation
Use an AI summary to check transcription, identify missing companion tests, and prepare questions. Use your clinician to determine whether the pattern represents lupus, Sjögren disease, systemic sclerosis, autoimmune thyroid disease, a medication effect, or healthy antibody positivity.
The Practical Bottom Line on ANA Results
ANA means antinuclear antibody, and a positive ANA is a clue rather than a diagnosis. The result warrants targeted follow-up when symptoms or companion tests suggest autoimmune organ involvement; otherwise, reassurance and observation are often appropriate.
The result deserves more attention when there is inflammatory arthritis, characteristic rash, mouth ulcers, Raynaud symptoms, low C3 or C4, low cell counts, proteinuria, or abnormal kidney sediment. The result deserves less attention when it is low-positive, isolated, and found during testing for nonspecific fatigue in an otherwise normal assessment.
Dr. Thomas Klein’s closing advice is to keep the original report, avoid self-diagnosis from a titre, and seek care promptly for kidney, breathing, chest, or neurologic symptoms. Most patients find that a focused plan is calmer and more medically useful than repeating every antibody.
For technical detail on how our AI handles laboratory context and safeguards, read the stiùireadh teicneòlais AI. A positive ANA is information—sometimes important information—but it is never the whole clinical story.
Aon seantans airson cuimhneachadh
A positive ANA tells us that antinuclear antibodies were detected; it does not tell us, by itself, whether you have an autoimmune disease, need treatment, or will become ill in the future.
Ceistean Bitheanta
Dè tha ANA a' ciallachadh air deuchainn fala?
Tha ANA a' seasamh airson antibody niùclasach an aghaidh. Lorg an deuchainn antibodies a cheanglas stuth taobh a-staigh niuclasalan cealla obair-lann, mar as trice air an aithris mar àicheil no deimhinneach le tiotal mar 1:80 no 1:320. Tha ANA a' cuideachadh luchd-clionaigeach a' measadh galar fèin-dìon stuth ceangail a dh'fhaodadh a bhith ann, ach chan urrainn dha lupus no suidheachadh eile a dhearbhadh leis fhèin. Tha comharran, toraidhean sgrùdaidh, sònrachas antibody, ìrean co-phàirteach, deuchainn fual, agus cunntasan fala a' dearbhadh dè a tha a' ciallachadh toradh deimhinneach.
An urrainn do dhuine fallain ANA deimhinneach a bhith aige?
Yes, a healthy person can have a positive ANA. In a U.S. population study using a 1:80 HEp-2 immunofluorescence cut-off, 13.8% of participants had ANA positivity, and prevalence increased with age (Satoh et al., 2012). Low-positive ANA results are therefore relatively common, especially in women and older adults. An isolated positive result without inflammatory symptoms or organ findings usually does not establish autoimmune disease.
Dè am tiotal ANA a thathas a' meas àrd?
Thathas den bheachd le mòran de na saotharlanna gu bheil tiotair ANA de 1:640 no nas àirde gu math àrd, fhad ‘s a tha 1:80 dearbhach ìosal agus gu tric thathas den bheachd gu bheil 1:160 gu 1:320 meadhanach. Chan eil na roinnean seo uile-choitcheann oir bidh saotharlannan a’ cleachdadh diofar fho-stratan, leughadairean, agus gearraidhean. Faodaidh ANA de 1:640 tachairt gun lupus, agus faodaidh tiotair nas ìsle a bhith cudromach ma tha proteinuria, dìth-chomais ìosal, no comharran sònraichte aig neach. Chan eil tiotair ANA leis fhèin a’ dearbhadh cho dona sa tha an galar no an fheum air làimhseachadh.
A bheil ANA deimhinneach a’ ciallachadh gu bheil lupus orm?
No, a positive ANA does not mean you have lupus. ANA positivity at 1:80 or greater is used as an entry criterion in the 2019 EULAR/ACR lupus classification system, but additional clinical and immunologic criteria are required (Aringer et al., 2019). Lupus assessment may include anti-dsDNA or anti-Sm antibodies, C3 and C4 complement, CBC, creatinine, urine protein, and a clinician’s examination. Many people with positive ANA never develop lupus.
Am bu chòir dhomh an deuchainn ANA agam ath-aithris ma tha e deimhinneach?
Chan eil feum aig a’ mhòr-chuid de dhaoine air deuchainn ANA ath-aithris às dèidh toradh dearbhach soilleir leis nach eil tiotalan ANA a’ nochdadh gu earbsach gnìomhachd galar fèin-dìonach. Dh’fhaodadh deuchainn ath-aithris a bhith reusanta ma bha dòigh obair-lann tùsail neo-shoilleir, bha an toradh aig a’ chrìoch, no gun nochd syndrome clionaigeach ùr às dèidh ùine fhada. Airson lupus air a bhith air a chreidsinn no air a stèidheachadh, bidh luchd-clionaigeach mar as trice a’ leantainn pròtain urine, creatinine, cunntasan fala, C3, C4, agus uaireannan anti-dsDNA seach ANA fhèin. Is e pàtran atharraichte de chomharran adhbhar nas fheàrr airson ath-sgrùdadh na àireamh ANA a chaidh atharrachadh.
Dèar canar a thèid a dhèanamh às dèidh ANA deimhinneach?
Leughaidhean às dèidh ANA dearbhach an crochadh air comharraidhean agus dh’fhaodadh iad a bhith a’ gabhail a-steach anti-dsDNA, anti-Sm, SSA/Ro, SSB/La, RNP, C3, C4, CBC, creatinine, urinalysis, agus co-mheas pròtain-gu-creatinine san urine. Feumaidh proteinuria aig 0.5 g no os a chionn gach latha, no co-mheas co-ionann, measadh clionaigeach sgiobalta nuair a tha comas ann gu bheil an dubhaig air a bhith mar thoradh air fèin-ghalar. Dh’fhaodadh laigse fèithe a bhith a’ brosnachadh creatine kinase no aldolase, agus dh’fhaodadh comharraidhean Raynaud a bhith a’ brosnachadh antibodies sònraichte do sglerosis siostaim. Chan eil pannalan antibody farsaing riatanach gu fèin-ghluasadach airson ANA singilte le dearbhadh ìosal.
Faigh Mion-sgrùdadh Deuchainn Fala le Cumhachd AI an-diugh
Thig còmhla ri còrr is 2 mhillean neach air feadh an t-saoghail a tha a’ earbsa Kantesti airson mion-sgrùdadh sa bhad, ceart air deuchainnean obair-lann. Luchdaich suas na toraidhean deuchainn fala agad agus faigh mìneachadh coileanta air biomarcair 15,000+ ann an diogan.
📚 Foillseachaidhean Rannsachaidh le Iomraidhean
Klein, T., Mitchell, S., & Weber, H. (2026). Frèam Dearbhaidh Clionaigeach v2.0 (Duilleag Dearbhaidh Meidigeach). Rannsachadh Leigheis AI Kantesti.
Klein, T., Mitchell, S., & Weber, H. (2026). Sgrùdadh Fala AI: Chaidh 2.5M de dheuchainnean a sgrùdadh | Aithisg Slàinte Cruinne 2026. Rannsachadh Leigheis AI Kantesti.
📖 Iomraidhean Meidigeach Taobh a-muigh
⚕️ Àicheadh Meidigeach
Tha an artaigil seo dìreach airson adhbharan foghlaim agus chan eil e a’ dèanamh comhairle mheidigeach. Cuir fios an-còmhnaidh gu solaraiche cùram slàinte teisteanasach airson co-dhùnaidhean breithneachaidh is leigheis.
Comharran earbsa E-E-A-T
Eòlas
Lèirmheas clionaigeach air a stiùireadh le lighiche air sruthan-obrach mìneachaidh obair-lann.
Eòlas
Fòcas air leigheas obair-lann air mar a bhios bith-chomharraidhean (biomarkers) a’ giùlan ann an co-theacsa clionaigeach.
Ùghdarrasachd
Air a sgrìobhadh le Dr. Thomas Klein le ath-sgrùdadh le Dr. Sarah Mitchell agus Prof. Dr. Hans Weber.
Earbsachd
Mìneachadh stèidhichte air fianais le slighean leanmhainn soilleir gus dragh a lughdachadh.